1
|
Morjen M, Zakraoui O, Abdelkafi-Koubaa Z, Srairi-Abid N, Marrakchi N, Essafi-Benkhadir K, Jebali J. CC5 and CC8, Two Disintegrin Isoforms from Cerastes cerastes Snake Venom Decreased Inflammation Response In Vitro and In Vivo. Int J Mol Sci 2023; 24:12427. [PMID: 37569801 PMCID: PMC10418880 DOI: 10.3390/ijms241512427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 07/27/2023] [Accepted: 07/31/2023] [Indexed: 08/13/2023] Open
Abstract
Inflammation is associated with many pathology disorders and the malignant progression of most cancers. Therefore, targeting inflammatory pathways could provide a promising strategy for disease prevention and treatment. In this study, we experimentally investigated the anti-inflammatory effect of CC5 and CC8, two disintegrin isoforms isolated from Cerastes cerastes snake venom, on LPS-stimulated macrophages, both on human THP-1 and mouse RAW264.7 cell adherence and their underlying mechanisms by measuring cytokine release levels and Western blot assay. Equally, both molecules were evaluated on a carrageenan-induced edema rat model. Our findings suggest that CC5 and CC8 were able to reduce adhesion of LPS-stimulated macrophages both on human THP-1 and mouse RAW264.7 cells to fibrinogen and vitronectin through the interaction with the αvβ3 integrin receptor. Moreover, CC5 and CC8 reduced the levels of reactive oxygen species (ROS) mediated by the NF-κB, MAPK and AKT signaling pathways that lead to decreased production of the pro-inflammatory cytokines TNF-α, IL-6 and IL-8 and increased secretion of IL-10 in LPS-stimulated THP-1 and RAW264.7 cells. Interestingly, both molecules potently exhibited an anti-inflammatory effect in vivo by reducing paw swelling in rats. In light of these results, we can propose the CC5 and CC8 disintegrins as interesting tools to design potential candidates against inflammatory-related diseases.
Collapse
Affiliation(s)
- Maram Morjen
- Laboratory of Biomolecules, Venoms and Theranostic Applications, LR20IPT01, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; (Z.A.-K.); (N.S.-A.); (N.M.)
| | - Ons Zakraoui
- Laboratory of Molecular Epidemiology and Experimental Pathology, LR16IPT04, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; (O.Z.); (K.E.-B.)
| | - Zaineb Abdelkafi-Koubaa
- Laboratory of Biomolecules, Venoms and Theranostic Applications, LR20IPT01, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; (Z.A.-K.); (N.S.-A.); (N.M.)
- Research Laboratory of Precision Medicine/Personalized Medicine and Oncology Investigation, LR21SP01, Salah Azaiez Institute, University of Tunis El Manar, Tunis 1007, Tunisia
| | - Najet Srairi-Abid
- Laboratory of Biomolecules, Venoms and Theranostic Applications, LR20IPT01, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; (Z.A.-K.); (N.S.-A.); (N.M.)
| | - Naziha Marrakchi
- Laboratory of Biomolecules, Venoms and Theranostic Applications, LR20IPT01, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; (Z.A.-K.); (N.S.-A.); (N.M.)
- Medicine School of Tunis, University of Tunis El Manar, 15 Djebel Lakhdhar Street, La Rabta, Tunis 1007, Tunisia
| | - Khadija Essafi-Benkhadir
- Laboratory of Molecular Epidemiology and Experimental Pathology, LR16IPT04, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; (O.Z.); (K.E.-B.)
| | - Jed Jebali
- Laboratory of Biomolecules, Venoms and Theranostic Applications, LR20IPT01, Pasteur Institute of Tunis, University of Tunis El Manar, Tunis 1002, Tunisia; (Z.A.-K.); (N.S.-A.); (N.M.)
| |
Collapse
|
2
|
Jlassi A, Manai M, Morjen M, Sahraoui G, Elasmi Allal M, ELBini-Dhouib I, Naija L, Charfi L, Rejaibi R, Ben Ahmed M, Marrakchi N, Srairi-Abid N, Mezlini A, Manai M, Mrad K, Doghri R. VISTA+/CD8+ status correlates with favorable prognosis in Epithelial ovarian cancer. PLoS One 2023; 18:e0278849. [PMID: 36952478 PMCID: PMC10035885 DOI: 10.1371/journal.pone.0278849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Accepted: 11/23/2022] [Indexed: 03/25/2023] Open
Abstract
Immunotherapy by blocking immune checkpoint regulators has emerged as a new targeted therapy for some cancers. Among them V-domain Ig suppressor of Tcell activation (VISTA) which is identified as a novel checkpoint regulator in ovarian cancer. This study aimed to investigate the VISTA role in Epithelial ovarian cancer (EOC), and its relationship with tumor-infiltrating lymphocytes (TILs) markers and its prognostic value. The expression of VISTA, CD3, CD8, CD4, FOXP3, and CD56 was assessed in 168 EOC tissue microarrays (TMA) by immunohistochemistry (IHC). In addition, associations between VISTA, TILs, clinicopathological variables, and overall survival (OS) were analyzed. VISTA expression in IGRov1 cells, as well as in PBMC of EOC patient, was evaluated by western blot. VISTA expression was detected in 64,28% of tissues, among which 42.3% were positive for tumor cells (TCs), and 47,9% were positive for immune cells (ICs). In univariate analysis, VISTA expression was significantly associated with a high density of TILs:CD3+ (p = 0,001), CD4+ (p = 0,002) and CD8+ (p≤0,001), in ICs but not in TCs. In terms of OS, multivariate analysis showed a significant association between the high density of CD8+ TILs and VISTA positive staining in ICs (p = 0,044), but not in TCs (p = 0,108). Kaplan-Meier curves demonstrated no correlation between VISTA expression and prolonged OS in both ICs (p = 0,841) and TCs (p = 0,090). Classification of EOC tumor microenvironment based on VISTA and CD8+TILs expression, demonstrated four immune subtypes: VISTA+/CD8+, VISTA+/CD8-, VISTA-/CD8+ and VISTA-/CD8-. The dual positive VISTA+/CD8+ subtype was significantly associated with prolonged OS in both TCs and ICs (p = 0,012 and p≤0,01, respectively), whereas patients with VISTA+/CD8- had the worst OS. Our results showed that VISTA is highly expressed in the IGRov1 cell line and LT-CD8 from a patient with EOC. Our results highlighted the association of VISTA expression and CD8+ TILs in EOC, with prolonged OS in patients with VISTA+/CD8+ and proposed VISTA as a potential immunotherapeutic target in EOC.
Collapse
Affiliation(s)
- Aida Jlassi
- Department of Biology, Mycology, Pathologies and Biomarkers Laboratory (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, Ariana, Tunisia
- Research Laboratory of Precision Medicine/Personalized Medicine and Oncology Investigation (LR21SP01), Tunis, Tunisia
| | - Maroua Manai
- Department of Biology, Mycology, Pathologies and Biomarkers Laboratory (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, Ariana, Tunisia
- Human Genetics Laboratory (LR99ES10), Faculty of Medicine of Tunis, University of Tunis, El Manar, Tunis, Tunisia
- Department of Medicine, Division of Hematology-oncology, New York, New York, United States of America
| | - Maram Morjen
- Laboratory of Biomolecules, Venoms and Theranostic Applications (LR20IPT01), Pasteur Institute of Tunis, University of Tunis, El Manar, Tunis, Tunisia
| | - Ghada Sahraoui
- Research Laboratory of Precision Medicine/Personalized Medicine and Oncology Investigation (LR21SP01), Tunis, Tunisia
- Department of Pathology, Salah Azaiez Institute, Tunis, Tunisia
- Faculty of Medicine of Tunis, University of Tunis, El Manar, Tunis, Tunisia
| | | | - Ines ELBini-Dhouib
- Laboratory of Biomolecules, Venoms and Theranostic Applications (LR20IPT01), Pasteur Institute of Tunis, University of Tunis, El Manar, Tunis, Tunisia
| | - Lamia Naija
- Faculty of Medicine of Tunis, University of Tunis, El Manar, Tunis, Tunisia
- Department of Surgical Oncology, Salah Aziz Institute, Tunis, Tunisia
| | - Lamia Charfi
- Research Laboratory of Precision Medicine/Personalized Medicine and Oncology Investigation (LR21SP01), Tunis, Tunisia
- Department of Pathology, Salah Azaiez Institute, Tunis, Tunisia
- Faculty of Medicine of Tunis, University of Tunis, El Manar, Tunis, Tunisia
| | - Rim Rejaibi
- Department of Biology, Mycology, Pathologies and Biomarkers Laboratory (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, Ariana, Tunisia
- Research Laboratory of Precision Medicine/Personalized Medicine and Oncology Investigation (LR21SP01), Tunis, Tunisia
- Department of Pathology, Salah Azaiez Institute, Tunis, Tunisia
| | - Melika Ben Ahmed
- Faculty of Medicine of Tunis, University of Tunis, El Manar, Tunis, Tunisia
- Laboratory of Transmission, Control and Immunobiology of Infections - LR16IPT02, Pasteur Institute of Tunis, University of Tunis, El Manar, Tunis, Tunisia
| | - Naziha Marrakchi
- Laboratory of Biomolecules, Venoms and Theranostic Applications (LR20IPT01), Pasteur Institute of Tunis, University of Tunis, El Manar, Tunis, Tunisia
| | - Najet Srairi-Abid
- Laboratory of Biomolecules, Venoms and Theranostic Applications (LR20IPT01), Pasteur Institute of Tunis, University of Tunis, El Manar, Tunis, Tunisia
| | - Amel Mezlini
- Research Laboratory of Precision Medicine/Personalized Medicine and Oncology Investigation (LR21SP01), Tunis, Tunisia
- Faculty of Medicine of Tunis, University of Tunis, El Manar, Tunis, Tunisia
- Department of Medical Oncology, Salah Aziz Institute, Tunis, Tunisia
| | - Mohamed Manai
- Department of Biology, Mycology, Pathologies and Biomarkers Laboratory (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, Ariana, Tunisia
| | - Karima Mrad
- Research Laboratory of Precision Medicine/Personalized Medicine and Oncology Investigation (LR21SP01), Tunis, Tunisia
- Department of Pathology, Salah Azaiez Institute, Tunis, Tunisia
- Faculty of Medicine of Tunis, University of Tunis, El Manar, Tunis, Tunisia
| | - Raoudha Doghri
- Research Laboratory of Precision Medicine/Personalized Medicine and Oncology Investigation (LR21SP01), Tunis, Tunisia
- Department of Pathology, Salah Azaiez Institute, Tunis, Tunisia
- Faculty of Medicine of Tunis, University of Tunis, El Manar, Tunis, Tunisia
| |
Collapse
|
3
|
Touihri-Barakati I, Kallech-Ziri O, Morjen M, Marrakchi N, Luis J, Hosni K. Inhibitory effect of phenolic extract from squirting cucumber ( Ecballium elaterium (L.) A. Rich) seed oil on integrin-mediated cell adhesion, migration and angiogenesis. RSC Adv 2022; 12:31747-31756. [PMID: 36380921 PMCID: PMC9638996 DOI: 10.1039/d2ra02593k] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Accepted: 11/01/2022] [Indexed: 03/10/2024] Open
Abstract
Integrin targeted therapies by natural bioactive compounds have attracted attention in the field of oncology and cancer treatment. This study evaluates the potential of phenolic extract from the medicinal herb Ecballium elaterium L. seed oil (PEO) to inhibit the adhesion and migration of the highly invasive human fibrosarcoma cell line HT1080. At safe concentrations (up to 40 μg mL-1), results show that PEO dose-dependently inhibits adhesion and migration of HT1080 to fibronectin (IC50 = 18 μg mL-1) and fibrinogen (IC50 = 12.86 μg mL-1). These observations were associated with the reduction of cell motility and migration velocity as revealed in the Boyden chamber and random motility using two-dimensional assays, respectively. Additional experiments using integrin blocking antibodies showed that PEO at the highest safe concentration (40 μg mL-1) competitively inhibited the attachment of HT1080 cell to anti-αvβ3 (>98%), anti-α5β1 (>86%), and to a lesser extent anti-α2 (>50%) immobilized antibodies, suggesting that αvβ3 and α5β1 integrins were selectively targeted by PEO. Moreover, PEO specifically targeted these integrins in human microvascular endothelial cells (HMEC-1) and dose-dependently blocked the in vitro tubulogenesis. In the CAM model, PEO inhibited the VEGF-induced neoangiogenesis confirming its anti-angiogenic effect. Collectively, these results indicate that PEO holds promise for the development of natural integrin-targeted therapies against fibrosarcoma.
Collapse
Affiliation(s)
- Imen Touihri-Barakati
- Laboratoire des Substances Naturelles (LR10INRAP02), Institut National de Recherche et d'Analyse Physico-chimique Sidi Thabet 2020 Ariana Tunisia
| | - Olfa Kallech-Ziri
- Laboratoire des Substances Naturelles (LR10INRAP02), Institut National de Recherche et d'Analyse Physico-chimique Sidi Thabet 2020 Ariana Tunisia
| | - Maram Morjen
- Laboratory of Biomolecules, Venoms and Theranostic Applications, LR20IPT01, Pasteur Institute of Tunis, University of Tunis El Manar Tunis 1002 Tunisia
| | - Naziha Marrakchi
- Laboratory of Biomolecules, Venoms and Theranostic Applications, LR20IPT01, Pasteur Institute of Tunis, University of Tunis El Manar Tunis 1002 Tunisia
| | - José Luis
- CNRS-UMR 7051, Institut de Neuro Physiopathologie (INP), Université Aix-Marseille 27 Bd Jean Moulin 13385 Marseille France
| | - Karim Hosni
- Laboratoire des Substances Naturelles (LR10INRAP02), Institut National de Recherche et d'Analyse Physico-chimique Sidi Thabet 2020 Ariana Tunisia
| |
Collapse
|
4
|
Morjen M, Othman H, Abdelkafi-Koubaa Z, Messadi E, Jebali J, El Ayeb M, Abid NS, Luis J, Marrakchi N. Targeting α1 inserted domain (I) of α1β1 integrin by Lebetin 2 from M. lebetina transmediterranea venom decreased tumorigenesis and angiogenesis. Int J Biol Macromol 2018; 117:790-799. [DOI: 10.1016/j.ijbiomac.2018.05.230] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Revised: 05/28/2018] [Accepted: 05/29/2018] [Indexed: 01/18/2023]
|
5
|
Ellijimi C, Ben Hammouda M, Othman H, Moslah W, Jebali J, Mabrouk HB, Morjen M, Haoues M, Luis J, Marrakchi N, Essafi-Benkhadir K, Srairi-Abid N. Helix aspersa maxima mucus exhibits antimelanogenic and antitumoral effects against melanoma cells. Biomed Pharmacother 2018; 101:871-880. [PMID: 29635896 DOI: 10.1016/j.biopha.2018.03.020] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Revised: 03/05/2018] [Accepted: 03/05/2018] [Indexed: 01/10/2023] Open
Abstract
Snail secretion is currently revolutionizing the world of cosmetics and human skin care. The efficacy of snail secretion in wounds healing has been proven both in vitro and by clinical studies. However, the potential anti-tumor effect of snail secretion was poorly investigated. In this report, our in vitro study showed that Helix aspersa maxima species snail slime (SS) could not only treat melanogenesis but also endowed with anti-tumoral activity against human melanoma cells. Indeed, SS reduced melanin content and tyrosinase activity on B16F10 cells with IC50 values of 288 μg/mL and 286 μg/mL, respectively, without altering cell viability. This effect was also observed, at a lesser extent, on human melanoma IGR-39 and SK-MEL-28 cell lines. On another hand, SS specifically inhibited the viability of IGR-39 and SK-MEL-28 cells associated to an apoptotic effect highlighted by PARP cleavage. It is worth to note that SS did not affect the viability of B16F10 cells and non tumorigenic HaCaT cells. Interestingly, this extract was found to inhibit migration and invasion of both human melanoma cells through reducing the expression of Matrix metalloproteinase MMP2. Snail slime also exerted a high inhibitory effect on IGR-39 cell adhesion through blocking the function of α2β1 (45%), αvβ3 (38%) integrins and by reducing the expression levels of αv and β1 integrins. The presented results shed light on the potential anti-melanoma effect of SS and support its use against skin diseases.
Collapse
Affiliation(s)
- Chedli Ellijimi
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire des Venins et biomolécules thérapeutiques LR11IPT08/ LR16IPT08, Tunis, 1002, Tunisia
| | - Manel Ben Hammouda
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire d'Epidémiologie Moléculaire et Pathologie Expérimentale appliquée aux Maladies infectieuses LR11IPT04/LR16IPT04, Tunis, 1002, Tunisia
| | - Houcemeddine Othman
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire des Venins et biomolécules thérapeutiques LR11IPT08/ LR16IPT08, Tunis, 1002, Tunisia
| | - Wassim Moslah
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire des Venins et biomolécules thérapeutiques LR11IPT08/ LR16IPT08, Tunis, 1002, Tunisia
| | - Jed Jebali
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire des Venins et biomolécules thérapeutiques LR11IPT08/ LR16IPT08, Tunis, 1002, Tunisia
| | - Hazem Ben Mabrouk
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire des Venins et biomolécules thérapeutiques LR11IPT08/ LR16IPT08, Tunis, 1002, Tunisia
| | - Maram Morjen
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire des Venins et biomolécules thérapeutiques LR11IPT08/ LR16IPT08, Tunis, 1002, Tunisia
| | - Meriam Haoues
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire de Recherche sur la Transmission, le Contrôle et l'Immunobiologie des Infections, LR11IPT02/ LR16IPT02 LTCII, Tunis, 1002, Tunisia
| | - José Luis
- INSERM UMR 911-Centre de Recherche en Oncologie Biologique et Oncopharmacologie (CRO2), Aix-Marseille Université, 27 Bd Jean Moulin, 13385, Marseille Cedex 5, France
| | - Naziha Marrakchi
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire des Venins et biomolécules thérapeutiques LR11IPT08/ LR16IPT08, Tunis, 1002, Tunisia
| | - Khadija Essafi-Benkhadir
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire d'Epidémiologie Moléculaire et Pathologie Expérimentale appliquée aux Maladies infectieuses LR11IPT04/LR16IPT04, Tunis, 1002, Tunisia
| | - Najet Srairi-Abid
- Université de Tunis El Manar, Institut Pasteur de Tunis, Laboratoire des Venins et biomolécules thérapeutiques LR11IPT08/ LR16IPT08, Tunis, 1002, Tunisia.
| |
Collapse
|
6
|
Taktak-BenAmar A, Morjen M, Ben Mabrouk H, Abdelmaksoud-Dammak R, Guerfali M, Fourati-Masmoudi N, Marrakchi N, Gargouri A. Expression, purification and functionality of bioactive recombinant human vascular endothelial growth factor VEGF 165 in E. coli. AMB Express 2017; 7:33. [PMID: 28168572 PMCID: PMC5293700 DOI: 10.1186/s13568-016-0300-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Accepted: 12/07/2016] [Indexed: 01/27/2023] Open
Abstract
Vascular endothelial growth factor (VEGF) is associated with tumour growth and metastasis. Because VEGF is the major player in both angiogenesis and vascular permeability and the most explored factor in angio-inhibitory therapies, many expression procedures have been developed to produce functional VEGF165 in convenient yield. In this study, recombinant human VEGF165 was cloned and expressed in Escherichia coli (BL21)-DE3 cells and large scale production was performed by fermentation. A high yield of active soluble protein was obtained after protein extraction employing both lysozyme and sonication treatment. Inclusion bodies were also isolated from the cell lysate and subjected to a simple protocol of solubilisation and refolding. Single-step purification was performed using nickel affinity chromatography and the purified proteins were able to recognize monoclonal Anti-poly-His antibody. The biological activity of the VEGF165 was successfully tested using the Chicken chorioallantoic membrane assay, wound-healing migration and proliferation assay on human umbilical vein endothelial cells (HUVEC).
Collapse
|
7
|
Bensaoud C, Abdelkafi-Koubaa Z, Ben Mabrouk H, Morjen M, Hmila I, Rhim A, Ayeb ME, Marrakchi N, Bouattour A, M'ghirbi Y. Hyalomma dromedarii (Acari: Ixodidae) Salivary Gland Extract Inhibits Angiogenesis and Exhibits In Vitro Antitumor Effects. J Med Entomol 2017; 54:1476-1482. [PMID: 29029126 DOI: 10.1093/jme/tjx153] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Indexed: 06/07/2023]
Abstract
Hard ticks (Acari: Ixodidae) are blood-sucking ectoparasites characterized by the extended period of their attachment to their host. To access their bloodmeal, ticks secrete saliva containing a range of molecules that target the host's inflammation, immune system, and hemostatic components. Some of these molecules reportedly possess antiangiogenic and antitumor properties. The present study describes our investigation, the first of its kind, of the antiangiogenic and antitumoral effects of the Hyalomma dromedarii Koch, 1844 (Acari: Ixodidae), salivary gland extract (SGE), which inhibited the adhesion and migration of Human Umbilical Vein Endothelial Cells (HUVECs) in a dose-dependent manner, as well as angiogenesis in the Chick Chorioallantoic Membrane model. Interestingly, H. dromedarii SGE exerted an antiproliferative effect on U87 glioblastoma cells and inhibited their adhesion and migration to fibrinogen. These results open up new possibilities for characterizing and developing new molecules involved in the key steps of tumor progression.
Collapse
Affiliation(s)
- Chaima Bensaoud
- Service d'entomologie médicale (LR11IPT03), Université Tunis El Manar, Institut Pasteur de Tunis, 1002 Tunis, Tunisia
| | - Zaineb Abdelkafi-Koubaa
- Laboratoire des Venins et Biomolécules Thérapeutiques (LR11IPT08), Institut Pasteur de Tunis, Université de Tunis El Manar, 1002 Tunis, Tunisia
| | - Hazem Ben Mabrouk
- Laboratoire des Venins et Biomolécules Thérapeutiques (LR11IPT08), Institut Pasteur de Tunis, Université de Tunis El Manar, 1002 Tunis, Tunisia
| | - Maram Morjen
- Laboratoire des Venins et Biomolécules Thérapeutiques (LR11IPT08), Institut Pasteur de Tunis, Université de Tunis El Manar, 1002 Tunis, Tunisia
| | - Issam Hmila
- laboratoire d'Epidémiologie et microbiologie vétérinaire (LR11IPT03), Université de Tunis El Manar, Institut Pasteur de Tunis, 1002 Tunis, Tunisia
| | - Adel Rhim
- Service d'entomologie médicale (LR11IPT03), Université Tunis El Manar, Institut Pasteur de Tunis, 1002 Tunis, Tunisia
| | - Mohamed El Ayeb
- Laboratoire des Venins et Biomolécules Thérapeutiques (LR11IPT08), Institut Pasteur de Tunis, Université de Tunis El Manar, 1002 Tunis, Tunisia
| | - Naziha Marrakchi
- Laboratoire des Venins et Biomolécules Thérapeutiques (LR11IPT08), Institut Pasteur de Tunis, Université de Tunis El Manar, 1002 Tunis, Tunisia
| | - Ali Bouattour
- Service d'entomologie médicale (LR11IPT03), Université Tunis El Manar, Institut Pasteur de Tunis, 1002 Tunis, Tunisia
| | - Youmna M'ghirbi
- Service d'entomologie médicale (LR11IPT03), Université Tunis El Manar, Institut Pasteur de Tunis, 1002 Tunis, Tunisia
| |
Collapse
|
8
|
Abdelkafi-Koubaa Z, Aissa I, Morjen M, Kharrat N, El Ayeb M, Gargouri Y, Srairi-Abid N, Marrakchi N. Interaction of a snake venom L-amino acid oxidase with different cell types membrane. Int J Biol Macromol 2015; 82:757-64. [PMID: 26433175 DOI: 10.1016/j.ijbiomac.2015.09.065] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2015] [Revised: 09/28/2015] [Accepted: 09/29/2015] [Indexed: 10/23/2022]
Abstract
Snake venom l-amino acid oxidases are multifunctional enzymes that exhibited a wide range of pharmacological activities. Although it has been established that these activities are primarily caused by the H2O2 generated in the enzymatic reaction, the molecular mechanism, however, has not been fully investigated. In this work, LAAO interaction with cytoplasmic membranes using different cell types and Langmuir interfacial monolayers was evaluated. The Cerastes cerastes venom LAAO (CC-LAAO) did not exhibit cytotoxic activities against erythrocytes and peripheral blood mononuclear cells (PBMC). However, CC-LAAO caused cytotoxicity on several cancer cell lines and induced platelet aggregation in dose-dependent manner. Furthermore, the enzyme showed remarkable effect against Gram-positive and Gram-negative bacteria. These activities were inhibited on the addition of catalase or substrate analogs, suggesting that H2O2 liberation× is required for these effects. Binding studies revealed that CC-LAAO binds to the cell surface and enables the production of highly localized concentration of H2O2 in or near the binding interfaces. On another hand, the interaction of CC-LAAO with a mimetic phospholipid film was evaluated, for the first time, using a monomolecular film technique. Results indicated that phospholipid/CC-LAAO interactions are not involved in their binding to membrane and in their pharmacological activities.
Collapse
Affiliation(s)
- Zaineb Abdelkafi-Koubaa
- Laboratoire des Venins et Biomolécules Thérapeutiques LR11IPT08, Institut Pasteur de Tunis, 13, Place Pasteur, 1002 Tunis, Tunisia; Université de Tunis el Manar, 1068 Tunis, Tunisia.
| | - Imen Aissa
- Laboratoire de Biochimie et de Génie Enzymatique des Lipases, Ecole Nationale d'Ingénieurs de Sfax (ENIS), Route de Soukra, BP 1173, 3038 Sfax, Tunisia; Université de Sfax, Tunisia
| | - Maram Morjen
- Laboratoire des Venins et Biomolécules Thérapeutiques LR11IPT08, Institut Pasteur de Tunis, 13, Place Pasteur, 1002 Tunis, Tunisia; Université de Tunis el Manar, 1068 Tunis, Tunisia
| | - Nadia Kharrat
- Laboratoire de Biochimie et de Génie Enzymatique des Lipases, Ecole Nationale d'Ingénieurs de Sfax (ENIS), Route de Soukra, BP 1173, 3038 Sfax, Tunisia; Université de Sfax, Tunisia
| | - Mohamed El Ayeb
- Laboratoire des Venins et Biomolécules Thérapeutiques LR11IPT08, Institut Pasteur de Tunis, 13, Place Pasteur, 1002 Tunis, Tunisia; Université de Tunis el Manar, 1068 Tunis, Tunisia
| | - Youssef Gargouri
- Laboratoire de Biochimie et de Génie Enzymatique des Lipases, Ecole Nationale d'Ingénieurs de Sfax (ENIS), Route de Soukra, BP 1173, 3038 Sfax, Tunisia; Université de Sfax, Tunisia
| | - Najet Srairi-Abid
- Laboratoire des Venins et Biomolécules Thérapeutiques LR11IPT08, Institut Pasteur de Tunis, 13, Place Pasteur, 1002 Tunis, Tunisia; Université de Tunis el Manar, 1068 Tunis, Tunisia
| | - Naziha Marrakchi
- Laboratoire des Venins et Biomolécules Thérapeutiques LR11IPT08, Institut Pasteur de Tunis, 13, Place Pasteur, 1002 Tunis, Tunisia; Université de Tunis el Manar, 1068 Tunis, Tunisia; Faculté de Médecine de Tunis, 1007 Tunis, Tunisia
| |
Collapse
|
9
|
Abdelkafi-Koubaa Z, Jebali J, Othman H, Morjen M, Aissa I, Zouari-Kesentini R, Bazaa A, Ellefi AA, Majdoub H, Srairi-Abid N, Gargouri Y, El Ayeb M, Marrakchi N. A thermoactive l-amino acid oxidase from Cerastes cerastes snake venom: Purification, biochemical and molecular characterization. Toxicon 2014; 89:32-44. [DOI: 10.1016/j.toxicon.2014.06.020] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2014] [Revised: 06/14/2014] [Accepted: 06/25/2014] [Indexed: 11/28/2022]
|
10
|
Morjen M, Honoré S, Bazaa A, Abdelkafi-Koubaa Z, Ellafi A, Mabrouk K, Kovacic H, El Ayeb M, Marrakchi N, Luis J. PIVL, a snake venom Kunitz-type serine protease inhibitor, inhibits in vitro and in vivo angiogenesis. Microvasc Res 2014; 95:149-56. [PMID: 25173589 DOI: 10.1016/j.mvr.2014.08.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2014] [Revised: 08/17/2014] [Accepted: 08/21/2014] [Indexed: 12/22/2022]
Abstract
Development and homeostasis of the vascular system requires integrin-promoting endothelial cell adhesion, migration and survival. Nowadays, integrins represent potential targets for pharmacological agents and open new avenues for the control of metastatic spread in the treatment of tumor malignancies. We have already reported that PIVL, a serine protease inhibitor isolated from Macrovipera lebetina venom, displays an anti-tumor effect through interference with integrin receptor function. Here, we report that PIVL inhibits human vascular endothelial cell adhesion and migration onto fibrinogen and fibronectin in a dose-dependent manner without any cytotoxicity. Furthermore, we show that PIVL increases microtubule dynamic instability in HMEC-1 transfected with EGFP-tagged α-tubulin. Using Matrigel™ and chick chorioallantoic membrane assays, we demonstrate that PIVL exhibits a strong anti-angiogenic effect both in vitro and in vivo. Interestingly, results herein reveal that the potent anti-angiogenic properties of PIVL are mediated by its RGD-like motif ((41)RGN(43)).
Collapse
Affiliation(s)
- Maram Morjen
- Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur de Tunis, Tunisia.
| | - Stéphane Honoré
- Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale, UMR_S 911, Marseille, France; APHM, Hôpital Timone, Service Pharmacie, Marseille, France
| | - Amine Bazaa
- Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur de Tunis, Tunisia
| | | | - Ameneallah Ellafi
- Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur de Tunis, Tunisia
| | - Kamel Mabrouk
- Equipe CROPS, Institut de Chimie Radicalaire - UMR 7273, Université d'Aix-Marseille, Site de Saint Jérôme, Av. Escadrille Normandie Niemen, 13397 Marseille, France
| | - Hervé Kovacic
- APHM, Hôpital Timone, Service Pharmacie, Marseille, France
| | - Mohamed El Ayeb
- Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur de Tunis, Tunisia
| | - Naziha Marrakchi
- Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur de Tunis, Tunisia; Faculté de Médecine de Tunis, Tunisia
| | - José Luis
- APHM, Hôpital Timone, Service Pharmacie, Marseille, France
| |
Collapse
|
11
|
Abdelkafi-Koubaa Z, Morjen M, Srairi-Abid N, El Ayeb M, Marrakchi N. [Snake Venom L-Amino Acid Oxidases potential biomedical applications]. Arch Inst Pasteur Tunis 2014; 91:15-32. [PMID: 26402967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
L-amino acid oxidases (LAAOs) are flavoenzymes widely found in several organisms, including venoms snakes, where they contribute to the toxicity of ophidian envenomation. Their toxicity is primarily due to enzymatic activity, but other mechanisms have been proposed recently which require further investigation. LAAOs exert biological and pharmacological effects, including actions on platelet aggregation and the induction of apoptosis, hemorrhage and cytotoxicity. These proteins present a high biotechnological potentialfor the development of antimicrobial, antitumor and antiprotozoan agents. This review summarizes the biochemical properties, structural characteristics and various biological functions of snake venoms' LAAO. Furthermore, the putative mechanisms of action, were well detailed.
Collapse
|
12
|
Morjen M, Abdelkafi-Koubaa Z, Luis J, Othman H, Srairi-Abid N, El Ayeb M, Marrakchi N. [Snake venom Kunitz/BPTI family: Structure, classification and pharmacological potential]. Arch Inst Pasteur Tunis 2014; 91:3-13. [PMID: 26402966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Snake venoms are rich sources of serine proteinase inhibitors that are members of the KunitzBPTI (bovine pancreatic trypsin inhibitor) family. Generally, these inhibitors are formed by 60 amino acids approximately. Their folding is characterised by a canonical loop that binds in a complementary manner to the active site of serine protease. Some variants from snake venoms show only weak inhibitory activity against proteases while others are neurotoxic. Moreover, proteases inhibitors are involved in various physiological prdcesses, such as blood coagulation, fibrinolysis, and inflammation. Also, these molecules showed an anti-tumoralpotent and anti-metastatic effect. Interestingly, KunitzBPTI peptides can have exquisite binding specificities and possess high potency for their targets making them excellent therapeutic candidates.
Collapse
|
13
|
Morjen M, Kallech-Ziri O, Bazaa A, Othman H, Mabrouk K, Zouari-Kessentini R, Sanz L, Calvete JJ, Srairi-Abid N, El Ayeb M, Luis J, Marrakchi N. PIVL, a new serine protease inhibitor from Macrovipera lebetina transmediterranea venom, impairs motility of human glioblastoma cells. Matrix Biol 2012; 32:52-62. [PMID: 23262217 DOI: 10.1016/j.matbio.2012.11.015] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2012] [Revised: 11/29/2012] [Accepted: 11/29/2012] [Indexed: 11/18/2022]
Abstract
A novel Kunitz-type serine proteinase inhibitor, termed PIVL, was purified to homogeneity from the venom of the Tunisian snake Macrovipera lebetina transmediterranea. It is a monomeric polypeptide chain cross-linked by three disulfide linkages with an isotope-averaged molecular mass of 7691.7 Da. The 67-residue full-length PIVL sequence was deduced from a venom gland cDNA clone. Structurally, PIVL is built by a single Kunitz/BPTI-like domain. Functionally, it is able to specifically inhibit trypsin activity. Interestingly, PIVL exhibits an anti-tumor effect and displays integrin inhibitory activity without being cytotoxic. Here we show that PIVL is able to dose-dependently inhibit the adhesion, migration and invasion of human glioblastoma U87 cells. Our results also show that PIVL impairs the function of αvβ3 and to a lesser extent, the activity of αvβ6, αvβ5, α1β1 and α5β1 integrins. Interestingly, we demonstrate that the (41)RGN(43) motif of PIVL is likely responsible for its anti-cancer effect. By using time lapse videomicroscopy, we found that PIVL significantly reduced U87 cells motility and affected cell directionality persistence by 68%. These findings reveal novel pharmacological effects for a Kunitz-type serine proteinase inhibitor.
Collapse
Affiliation(s)
- Maram Morjen
- Laboratoire des Venins et Biomolécules Thérapeutiques, Institut Pasteur de Tunis, Tunisia.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Jebali J, Jeanneau C, Morjen M, Mathieu S, Bazaa A, el Ayeb M, Luis J, Gargouri A, Marrakchi N, el Battari A. Expression of a functional recombinant C-type lectin-like protein lebecetin in the human embryonic kidney cells. Biotechnol Prog 2012; 28:1560-5. [DOI: 10.1002/btpr.1632] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2012] [Revised: 08/14/2012] [Indexed: 11/08/2022]
|
15
|
Ayed Y, Bousabbeh M, Mabrouk HB, Morjen M, Marrakchi N, Bacha H. Impairment of the cell-to-matrix adhesion and cytotoxicity induced by the Mediterranean jellyfish Pelagia noctiluca venom and its fractions in cultured glioblastoma cells. Lipids Health Dis 2012; 11:84. [PMID: 22741917 PMCID: PMC3537653 DOI: 10.1186/1476-511x-11-84] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2012] [Accepted: 06/28/2012] [Indexed: 11/10/2022] Open
Abstract
Background The biodiversity of the marine environment and the associated chemical diversity constitute a practically unlimited source of new active substances in the field of the development of bioactive products. In our study, we have investigated the efficiency of the venom from the Mediterranean jellyfish, Pelagia noctiluca and its fractions for anti-proliferative and anti-cell adhesion to cell–extracellular matrix activities. Results Our experiments have indicated that the separation of the Mediterranean jellyfish Pelagia noctiluca crude venom extract by sephadex G-75 chromatography led to four fractions (F1, F2, F3, and F4). Among the four fractions F1 and F3 were cytotoxic against U87 cells with IC50 values of 125 and 179 μg/ml respectively. The venom, F1, F2 and F 3 showed significant anti-proliferative activity in time-dependent manner. Our results also suggest that these fractions and the venom are able to inhibit cell adhesion to fibrinogen in dose-dependent manner. This inhibition is reliant on its ability to interact with integrins. Conclusions To conclude, we have demonstrated for the first time that Pelagia noctiluca venom and its fractions especially (F1 and F2) display potent anti-tumoral properties. Separation by sephadex G-75 chromatography give rise to more active fractions than the crude venom extract. The purification and the determination of chemical structures of compounds of these active fractions are under investigation. Overall, Pelagia noctiluca venom may has the potential to serve as a template for future anticancer-drug development.
Collapse
Affiliation(s)
- Yosra Ayed
- Laboratory for Research on Biologically Compatible Compounds, Faculty of Dentistry, Rue Avicenne, Monastir 5019, Tunisia
| | | | | | | | | | | |
Collapse
|